Pfizer Inc. $PFE Holdings Cut by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA reduced its stake in Pfizer Inc. (NYSE:PFE) by 32.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 64,102 shares of the biopharmaceutical company’s stock after selling 31,348 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Pfizer were worth $1,699,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Horizon Financial Services LLC grew its position in shares of Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 645 shares during the last quarter. YANKCOM Partnership acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $28,000. Grey Fox Wealth Advisors LLC acquired a new position in shares of Pfizer during the third quarter worth approximately $29,000. Darwin Wealth Management LLC bought a new position in Pfizer in the 2nd quarter worth approximately $32,000. Finally, True Wealth Design LLC increased its position in Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 974 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Board declared a $0.43 Q2 dividend (payable June 12; record/ex‑div May 8), the 350th consecutive quarterly payout — supports income investors and signals cash‑flow confidence. Pfizer Declares Second-Quarter 2026 Dividend
• Positive Sentiment: Pfizer’s GLP‑1 weight‑management drug Xianweiying is available for pre‑order in China — early commercialization there could materially expand revenue opportunity versus peers. Pfizer GLP-1 weight loss drug available for pre-order in China
• Positive Sentiment: Company to present broad oncology pipeline data at ASCO (multiple abstracts, late‑breaking sessions) — positive for long‑term growth if trial readouts show benefit. Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
• Neutral Sentiment: Analysts maintain mixed views — the consensus rating is “Hold,” reflecting cautious expectations despite recent execution. Pfizer Inc. (NYSE:PFE) Given Consensus Rating of “Hold” by Analysts
• Neutral Sentiment: Preview pieces note Pfizer’s history of modest earnings beats and margin improvement from cost cuts — upcoming results could surprise but uncertainties (patent cliffs, product mix) remain. Pfizer Could Surprise Again This Earnings Season (Preview)
• Negative Sentiment: Barclays reiterated a “Sell” — a high‑profile sell rating increases downward pressure on sentiment and trading. Barclays Remains a Sell on Pfizer (PFE)
• Negative Sentiment: Royal Bank of Canada assigned an Underperform — another downgrade that can pressure the share price and reduce buy‑side conviction. Pfizer (NYSE:PFE) Earns Underperform Rating from Royal Bank Of Canada
• Negative Sentiment: Top strategy executive is leaving — leadership turnover creates short‑term execution risk and may add to investor caution. Pfizer’s top strategy executive is leaving

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on PFE shares. Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Guggenheim boosted their target price on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Morgan Stanley lifted their price target on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Finally, Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $28.48.

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.78 on Thursday. The stock has a market cap of $152.28 billion, a PE ratio of 19.69 and a beta of 0.43. Pfizer Inc. has a 12 month low of $21.97 and a 12 month high of $28.75. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The business has a fifty day simple moving average of $27.26 and a 200-day simple moving average of $26.05.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the prior year, the business earned $0.63 EPS. The business’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is currently 126.47%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.